

## **PBI-200**

**Name:** PBI-200

**Synonyms:** PBI 200

**Indication:** Solid Tumor Cancers

**Company:** Pyramid Bio

PBI-200, a best-in-class, orally active TRK inhibitor. PBI-200 is a highly brain penetrant agent which overcomes the acquired clinical resistance mutations that are observed with current TRK inhibitor therapies. It is intended to treat a broad range of genomically-defined solid tumor cancers, including primary and metastatic brain cancers.

In Oncology, where precision medicine strategies have been utilized for the treatment of various solid and liquid tumors.

Pyramid Biosciences is dedicated to discovering and developing targeted therapeutics for a wide range of disorders that are regulated by the tropomyosin receptor kinase (TRK) family. By precisely and selectively modulating the actions of these fundamental cell surface receptors, we can control the key signaling pathways responsible for a patient's disease, condition or symptoms.